FAVIVIR contains Favipiravir. Favipiravir is a novel antiviral compound that selectively and potently inhibits the RNA dependent RNA polymerase (RdRP) of influenza and many other RNA viruses. It has been found to inhibit all serotypes and strains of influenza A, B and C viruses against which it has been tested, including those resistant to other therapies. Favipiravir is currently the drug under investigation for COVID-19.
INDICATIONS
Antiviral treatment for Moderate and hospitalized cases of Covid-19
DOSAGE AND ADMINISTRATION
Two loading doses of 1800mg each on day one, followed by two maintenance doses of 800mg every day until the course is finished at 14 days.
WARNINGS AND PRECAUTIONS
Favipiravir is currently being investigated in the treatment of COVID-19. Hence, all the precautions and warnings are not yet known in this set of patients.
